Compare DX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DX | ABCL |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 1994 | 2020 |
| Metric | DX | ABCL |
|---|---|---|
| Price | $12.52 | $10.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $14.75 | $8.40 |
| AVG Volume (30 Days) | 4.3M | ★ 6.6M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | ★ 65.77 | 10.91 |
| EPS | ★ 0.45 | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | $28.51 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $11.83 | $2.75 |
| 52 Week High | $14.93 | $12.58 |
| Indicator | DX | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 50.98 |
| Support Level | $12.14 | $10.44 |
| Resistance Level | $13.29 | $12.58 |
| Average True Range (ATR) | 0.16 | 0.65 |
| MACD | -0.03 | -0.29 |
| Stochastic Oscillator | 10.97 | 0.70 |
Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.